DK2909169T3 - Krystallinsk fase af (3s,3s') 4,4'-disulfandiylbis(3-aminobutan 1-sulfonsyre) med l-lysin - Google Patents
Krystallinsk fase af (3s,3s') 4,4'-disulfandiylbis(3-aminobutan 1-sulfonsyre) med l-lysin Download PDFInfo
- Publication number
- DK2909169T3 DK2909169T3 DK13779603.3T DK13779603T DK2909169T3 DK 2909169 T3 DK2909169 T3 DK 2909169T3 DK 13779603 T DK13779603 T DK 13779603T DK 2909169 T3 DK2909169 T3 DK 2909169T3
- Authority
- DK
- Denmark
- Prior art keywords
- absd
- lysine
- crystalline form
- phase
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/26—Separation; Purification; Stabilisation; Use of additives
- C07C319/28—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Krystallinsk form af (3S,3S')4,4'-clisulfancliylbis(3-aminobutan-l-sulfonsyre) ABSD med L-lysin.
2. Den krystallinske form ifølge krav 1, hvor støkiometrien af den krystallinske form er <ABSD.(L-lysin)2>.
3. Den krystallinske form ifølge krav 1 eller 2, hvor røntgendiffraktionsmønsteret af den krystallinske form omfatter de følgende toppe:
hvor røntgendiffraktionsmønsteret er opnået med en Cu Ka-anode.
4. Proces til fremstillingen afen krystallinsk form af ABSD og L-lysin, omfattende trinnene: a. at bringe ABSD, eller et salt deraf, eller blandinger deraf, i kontakt med L-lysin, b. eventuelt at udløse dannelsen afen krystallinsk fase, og/eller eventuelt at forbedre krystalliniteten af den krystallinske fase, c. at isolere den krystallinske fase opnået i trin (b) (eller (a)).
5. Processen ifølge krav 4, hvor ABSD:L-lysin-støkiometrien i trin (a) er omfattet mellem 1:1,5 og 1:2,5.
6. Processen ifølge krav 4 eller 5, hvor trin (a) udføres i opløsning.
7. Processen ifølge krav 6, hvor ABSD og L-lysin er opslæmmet i vand.
8. Processen ifølge krav 4 eller 5, hvor trin (a) udføres i fast tilstand, fortrinsvis ved højenergi-malning.
9. Processen ifølge krav 6, hvor trin (b) udføres ved tilsætning af et antisolvent, fortrinsvis ethanol.
10. Processen ifølge et hvilket som helst af kravene 4 til 9, hvor forbedringen af krystalliniteten af trin (b) udføres ved en temperaturcyklus.
11. Processen ifølge krav 10, hvor temperaturcyklen gentages flere gange.
12. Processen ifølge krav 11, hvor temperaturcyklen gentages mellem 5 og 15 gange, fortrinsvis 10 gange.
13. Farmaceutisk sammensætning omfattende den krystallinske form ifølge et hvilket som helst af kravene 1 til 3, i kombination med en farmaceutisk acceptabel bærer eller fortynder.
14. Den krystallinske form ifølge et hvilket som helst af kravene 1 til 3, eller den farmaceutiske sammensætning ifølge krav 13, til anvendelse i behandlingen af forhøjet blodtryk og/eller relaterede sygdomme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306307.5A EP2722327A1 (en) | 2012-10-22 | 2012-10-22 | Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine |
| PCT/EP2013/072028 WO2014064077A1 (en) | 2012-10-22 | 2013-10-22 | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2909169T3 true DK2909169T3 (da) | 2018-02-26 |
Family
ID=47278723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13779603.3T DK2909169T3 (da) | 2012-10-22 | 2013-10-22 | Krystallinsk fase af (3s,3s') 4,4'-disulfandiylbis(3-aminobutan 1-sulfonsyre) med l-lysin |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9278921B2 (da) |
| EP (2) | EP2722327A1 (da) |
| JP (1) | JP6317358B2 (da) |
| KR (1) | KR102103407B1 (da) |
| CN (1) | CN104768927B (da) |
| AR (1) | AR093070A1 (da) |
| AU (1) | AU2013336738B2 (da) |
| BR (1) | BR112015008931B1 (da) |
| CA (1) | CA2884914C (da) |
| CY (1) | CY1119913T1 (da) |
| DK (1) | DK2909169T3 (da) |
| EA (1) | EA024460B1 (da) |
| ES (1) | ES2658413T3 (da) |
| HK (1) | HK1212321A1 (da) |
| HR (1) | HRP20180189T1 (da) |
| HU (1) | HUE036037T2 (da) |
| IL (1) | IL237733B (da) |
| IN (1) | IN2015DN02807A (da) |
| LT (1) | LT2909169T (da) |
| ME (1) | ME02955B (da) |
| MX (1) | MX353693B (da) |
| NO (1) | NO2909169T3 (da) |
| NZ (1) | NZ706070A (da) |
| PL (1) | PL2909169T3 (da) |
| PT (1) | PT2909169T (da) |
| RS (1) | RS56896B1 (da) |
| SI (1) | SI2909169T1 (da) |
| TW (1) | TWI643842B (da) |
| WO (1) | WO2014064077A1 (da) |
| ZA (1) | ZA201503574B (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103951562B (zh) * | 2014-05-09 | 2016-04-20 | 四川九章生物化工科技发展有限公司 | 一种绿原酸晶型及其制备方法 |
| WO2022225712A1 (en) * | 2021-04-22 | 2022-10-27 | Teva Pharmaceuticals International Gmbh | Solid state forms of firibastat and processes for preparation thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004007441A2 (fr) | 2002-07-16 | 2004-01-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Derives de 4,4' -dithiobis- (3-aminobutane-1-sulfonates) nouveaux et compositions les contenant |
| FR2858617A1 (fr) * | 2003-08-06 | 2005-02-11 | Inst Nat Sante Rech Med | Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| EP2439192A1 (en) | 2010-10-07 | 2012-04-11 | Quantum Genomics | Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) |
| US9447050B2 (en) * | 2011-04-05 | 2016-09-20 | The Translational Genomics Research Institute | Solid forms of curcumin |
-
2012
- 2012-10-22 EP EP12306307.5A patent/EP2722327A1/en not_active Withdrawn
-
2013
- 2013-10-18 AR ARP130103795A patent/AR093070A1/es unknown
- 2013-10-22 AU AU2013336738A patent/AU2013336738B2/en active Active
- 2013-10-22 ES ES13779603.3T patent/ES2658413T3/es active Active
- 2013-10-22 ME MEP-2018-29A patent/ME02955B/me unknown
- 2013-10-22 LT LTEP13779603.3T patent/LT2909169T/lt unknown
- 2013-10-22 BR BR112015008931-3A patent/BR112015008931B1/pt active IP Right Grant
- 2013-10-22 PT PT137796033T patent/PT2909169T/pt unknown
- 2013-10-22 WO PCT/EP2013/072028 patent/WO2014064077A1/en active Application Filing
- 2013-10-22 SI SI201330952T patent/SI2909169T1/en unknown
- 2013-10-22 CN CN201380052793.5A patent/CN104768927B/zh active Active
- 2013-10-22 CA CA2884914A patent/CA2884914C/en active Active
- 2013-10-22 IN IN2807DEN2015 patent/IN2015DN02807A/en unknown
- 2013-10-22 NO NO13779603A patent/NO2909169T3/no unknown
- 2013-10-22 EA EA201500438A patent/EA024460B1/ru unknown
- 2013-10-22 JP JP2015537299A patent/JP6317358B2/ja active Active
- 2013-10-22 US US14/437,343 patent/US9278921B2/en not_active Expired - Fee Related
- 2013-10-22 HU HUE13779603A patent/HUE036037T2/hu unknown
- 2013-10-22 MX MX2015005059A patent/MX353693B/es active IP Right Grant
- 2013-10-22 DK DK13779603.3T patent/DK2909169T3/da active
- 2013-10-22 TW TW102138122A patent/TWI643842B/zh active
- 2013-10-22 PL PL13779603T patent/PL2909169T3/pl unknown
- 2013-10-22 RS RS20180133A patent/RS56896B1/sr unknown
- 2013-10-22 EP EP13779603.3A patent/EP2909169B1/en active Active
- 2013-10-22 KR KR1020157013661A patent/KR102103407B1/ko active IP Right Grant
- 2013-10-22 NZ NZ706070A patent/NZ706070A/en unknown
-
2015
- 2015-03-12 IL IL237733A patent/IL237733B/en active IP Right Grant
- 2015-05-21 ZA ZA2015/03574A patent/ZA201503574B/en unknown
- 2015-12-31 HK HK15112915.0A patent/HK1212321A1/xx not_active IP Right Cessation
-
2016
- 2016-02-01 US US15/012,625 patent/US9487477B2/en active Active
-
2018
- 2018-02-01 HR HRP20180189TT patent/HRP20180189T1/hr unknown
- 2018-02-14 CY CY20181100179T patent/CY1119913T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2652187T3 (es) | Fenilacetato de l-ornitina y métodos para elaborar el mismo | |
| FI108637B (fi) | Menetelmä lääkeaineena käyttökelpoisen (+)-(S)-2-(3-bentsoyylifenyyli)propaanihapon trometamiinisuolan valmistamiseksi | |
| US10183915B2 (en) | Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof | |
| ES2720148T3 (es) | Métodos de fabricación de fenilacetato de L-ornitina | |
| AU2015221466B2 (en) | L-ornithine phenyl acetate and methods of making thereof | |
| US10532988B2 (en) | Crystalline forms of neurotrophin mimetic compounds and their salts | |
| KR20210097100A (ko) | 2-(1-아실옥시-n-펜틸)벤조산 및 염기성 아미노산 또는 아미노구아니딘이 형성하는 염, 이의 제조 방법 및 용도 | |
| US20090170945A1 (en) | Pregabalin salts | |
| KR102405199B1 (ko) | 설카딘 염 | |
| PT2882753T (pt) | Processo para a preparação de pemetrexed e sal de lisina do mesmo | |
| DK2909169T3 (da) | Krystallinsk fase af (3s,3s') 4,4'-disulfandiylbis(3-aminobutan 1-sulfonsyre) med l-lysin | |
| US11225467B2 (en) | Crystalline forms of neurotrophin mimetic compounds and their salts | |
| JP2017505788A (ja) | イオンチャネルモジュレーターの固体形態 | |
| US11440908B2 (en) | Crystalline forms of dasatinib | |
| KR101007927B1 (ko) | 시부트라민-ｌ-카르니틴 다이술폰산염, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| WO2019160940A1 (en) | Glucagon receptor antagonists |